BUZZ-<a href="https://laohu8.com/S/LUCD">Lucid Diagnostics</a> rises after winning VA contract for cancer test** Shares of cancer‑test developer Lucid Diagnostics LUCD.O rise 3.31% to $1.25 premarket
** Co says it has secured a U.S. Veterans Affairs contract for EsoGuard, its test that checks for DNA changes linked to early esophageal cancer
** Esophageal cancer often begins as damage from long‑term heartburn and EsoGuard uses a quick office procedure to collect cells and screen for these changes, per LUCD
** Says VA hospitals and clinics nationwide can now buy the test at Medicare‑matched pricing, giving more than 9 million people access to early esophageal cancer screening
** LUCD gained ~33% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments